undamentalytics Newsletter
Sign in

Starling Oncology, Inc. (STLN) stock

Add to watchlist

Add holding +

NASDAQ: STLN Nasdaq Health Care Services Next results ~November 5, 2026

C Fundamentals grade

Starling Oncology, Inc. is a US-listed company in the health care services industry. Its financial year ends in December.

Stock price today

Loading chart…

Third-party market data · may be delayed

Model estimate per share

~$9.5

Valuation models combined (3)

Base case. Range ~$6.8–$12. Weighted average of 3 models (growth cash-flow model, forward price-to-sales vs peers, revenue-to-maturity model), the growth cash-flow model counting double.

Price vs value

No Buy/Hold/Sell rating is issued: valued with our growth model, which doesn't carry a Buy/Hold/Sell rating yet.

Starling Oncology, Inc. valuation: adjust assumptions and compare models →

Who’s trading

What company insiders, investment funds and members of Congress have been doing with the stock, from their own filings.

  • Insiders1 buying, 5 selling16 purchases and 11 sales by directors and officers, last 12 monthsInsider trades
  • Funds78 adding, 46 cuttingOf 28 active managers that changed their stake, 18 added; quarter to June 30, 2026Fund buyers and sellers

Value diary

Our note on each quarter Starling Oncology files

Where Starling Oncology stands after its latest 10-Q

Revenue for the twelve months to June 2026 was $587m, up 38.4% on a year earlier, faster than the 35.4% growth a quarter earlier. That growth ranks 3 of 34 among the health care services companies we cover. Free-cash-flow margin rose to -0.6% from -3.1% a year earlier. Operating margin widened to -4.4% from -11.1%. The diluted share count is up 25.7% on a year earlier, which dilutes existing holders. Against its peers on growth, profitability, cash generation and balance sheet, it grades C. It passes 2 of our 5 financial-health checks. Our revenue-to-maturity cash-flow model value is $11.79 a share, against a share price of $6.73.

Source: 10-Q filed August 6, 2026 on SEC EDGAR · Financials · Valuation

Written from the company's filings and our models when each quarter's report arrives. Figures in older notes are as published at the time. Not investment advice.

The Fundamentalytics view

Next results ~November 5, 2026 (estimated)

Starling Oncology, Inc.'s trailing-twelve-month revenue grew 38.4% year on year, with a free-cash-flow margin of -0.6%. Where it stands out: revenue growth of 38.4% ranks 5 of 41 health care services companies we cover. Where it lags: change in share count of 25.7% ranks 35 of 39 health care services companies we cover.

Current signal Free cash flow diverging from earnings: TTM free cash flow grew 75.2% while net income grew 44.9%: a 30pp divergence.

Assembled from SEC-filed figures — the full workings are on this page and in our methodology. Observations, not recommendations.

Highlights

How we pick these

Strengths

  • Fast growth. Revenue grew 38.4% over the last 12 months, against a median of 7.3% for health care services companies we cover.
  • Growth speeding up. The growth rate is 3.0 points higher than a quarter earlier.
  • Margins widening. Operating margin is up 6.6 points on a year ago.

Things to watch

  • Loss-making. Operating margin is -4.4%: costs exceed revenue.
  • Burning cash. Free cash flow was -0.6% of revenue over the last 12 months.
  • Share dilution. Diluted shares rose 25.7% in a year.
  • Volatile shares. Over the past year the shares showed annualised volatility of 80% and a beta of 1.6 against the S&P 500.
  • Below peers: long-term debt as % of assets. Long-term debt as % of assets of 44.8% ranks 26 of 31 health care services companies we cover (median 27.7%).
  • Missing expectations. Earnings per share fell short of the consensus estimate in 2 of the last four quarters.

Latest results: FY2026 Q2

Filed August 6, 2026
Earnings per share
-$0.08 against an average estimate of -$0.06: missed by 25.0%
Revenue
$161m, up 34.6% on a year earlier
Share reaction
+27.4% in the first session after the results on August 6, 2026, against +0.5% for the S&P 500
Next report
November 5, 2026

Starling Oncology's figures from its SEC filings and results release; estimates are the analysts' average. Not a recommendation.

Price chart

  • 1 day-4.3%
  • 1 week-0.6%
  • 1 month-1.6%
  • This year+75.6%
  • 1 year+40.1%
  • 5 years-37.4%
  • S&P 500 this year+11.2%

Closing prices to 2026-11-02. Price change only, dividends excluded.

Loading chart…

Third-party market data · may be delayed

At a glance

Trailing twelve months, from SEC filings

Profitability

Revenue (TTM)
$587M
Operating margin
-4.4%
Net margin
-6.2%
EPS (TTM, diluted)
$-0.36

Growth

Revenue growth
+38.4%
Change in growth rate
+3.0 pts
Share count change
+25.7%

Cash

Free cash flow (TTM)
-$3.3M
FCF margin
-0.6%
Stock pay % of revenue
0.9%

Earnings

Last results
August 6, 2026

News & updates

Updated October 31, 2026

Company announcements, filed results and changes that matter to shareholders.

  1. Leadership
  2. Agreement
  3. Insider trade
  4. Results
  5. Announcement
  6. Agreement

Refreshed hourly when new source data is available. Summaries are checked against company releases and SEC filings. Company announcement headlines are labelled when a checked summary is unavailable.

Valuation

Starling Oncology, Inc. valuation models and calculator

Fundamentalytics rating

model v1.6 · 2026-11-03

Not rated: valued with our growth model, which doesn't carry a Buy/Hold/Sell rating yet.

Valuation models

We value Starling Oncology, Inc. as an operating company, with every model that fits that kind of business. Cost of equity 8.3%: the 10-year Treasury yield (4.9%) plus a beta of 0.75 times a 4.5% equity risk premium.

Value per share by model
Model Value per share In the combined value?
Growth cash-flow model Revenue for this year and next from analysts' consensus, then growth fading to 2.5%; the operating margin moving to profitable peers'; investment needed per dollar of growth from peers; reduced by a failure probability. For young or fast-growing companies. The starting margin is normalized to between -100% and 60%; net margin is a proxy when operating income is not tagged. Uses analysts' consensus estimates (third-party data), not our forecasts. ~$9.0 ~$5.0–$12 Primary model, counts double
Price-to-earnings vs peers Earnings per share times peers' typical (harmonic-mean) price-to-earnings. — Does not apply: no positive earnings in the latest twelve months
Residual income Book value plus the present value of returns above the cost of equity, fading over ten years. — Does not apply: book value or earnings not available
Justified price-to-book Book value times (return on equity - growth) / (cost of equity - growth): steady-state returns. — Does not apply: return on equity is not positive
Forward price-to-sales vs peers Next year's consensus sales per share times peers' typical forward price-to-sales; only when earnings are negative. Uses analysts' consensus estimates (third-party data), not our forecasts. ~$6.8 ~$6.8–$20 Included, half weight
Revenue-to-maturity model Revenue grown to maturity with the cash margin moving to the industry's; for companies not yet profitable. ~$12 ~$9.5–$14 Included
Combined value Weighted average of the models that apply: the primary model (growth cash-flow model) counts double. Models more than 5x or less than 0.2x the share price, or more than 3x away from the other models' median, are left out. ~$9.5 ~$6.8–$12 3 models

Different models fail in different ways, so where several apply we average them rather than trust one. Peer-based models compare Starling Oncology, Inc. with Health Care Services in our coverage, using third-party market data. Model values are estimates under stated assumptions, updated as new filings arrive; not price targets or investment advice. How each model works.

Valuation multiples over time Market data may be delayed

At fiscal year end 202020212022202320242025Now
Share price$10.80$9.75$1.65$2.04$0.31$3.56$6.25
Market value$638m$646m$133m$150m$23m$329m$631m
+ Net debt (− = net cash)$11m−$115m$96m$77m$60m$52m$45m
Enterprise value$650m$531m$229m$227m$84m$381m$676m
Multiples
Price / sales 3.4x3.2x0.5x0.5x0.1x0.7x1.1x
Price / earnings ——n/m————
Price / free cash flow ———————
EV / EBITDA ———————

Market value uses the period's diluted share count; figures for each fiscal year use that year's results and the price at year end. "Now" uses today's price and the last twelve months.

Moat

12 /100

Weak moat

How hard Starling Oncology's competitive advantage looks for rivals to wear away, judged from 6 years of its own filings: returns on capital, pricing power, profit durability, cash conversion and discipline.

  • Returns on capital 0 / 20

    Net income has been a median -23.4% of total assets over 6 years.

  • Durability 10 / 20

    Operating margin has been a median -17.6%; its worst year was -36.1%.

  • Cash conversion 0 / 20

    Free cash flow was positive in 0 of 5 years, at a median -13.3% of revenue.

AI disruption exposure: Medium. In this industry, AI could change how the product is made or sold, without replacing the core asset. The score above includes a 5-point deduction for that exposure (17 before it).

A rules-based reading of reported figures, not a forecast and not investment advice. How the score is built: methodology.

Forecasts and guidance

Next results: November 5, 2026, after the close. Analysts expect revenue of $169m for the quarter.

Analysts' consensus

Fiscal yearEPSGrowthRevenueGrowth
Current −$0.16 +70% $665m +32%
Next $0.00 +100% $884m +33%

How the EPS forecast has moved

The consensus EPS forecast for the current fiscal year is +17.4% on 90 days ago. In the last 30 days, 0 analysts raised Starling Oncology, Inc.'s forecast and 4 cut it.

Consensus EPS forecast Starling Oncology, Inc., last 90 days
−$0.20 −$0.15 −$0.10 −$0.05 $0.00 90 days ago 60 days ago 30 days ago 7 days ago Now Current fiscal year, 90 days ago: −$0.14 Current fiscal year, 60 days ago: −$0.16 Current fiscal year, 30 days ago: −$0.16 Current fiscal year, 7 days ago: −$0.16 Current fiscal year, Now: −$0.16 −$0.16

Average of analysts' published estimates (third-party data).

View chart data
Period Current fiscal year
90 days ago −$0.14
60 days ago −$0.16
30 days ago −$0.16
7 days ago −$0.16
Now −$0.16

Earnings against estimates

Quarter toEstimateActualSurprise
Jun 2026 −$0.06 −$0.08 −25.0%
Mar 2026 −$0.09 −$0.02 +77.1%
Dec 2025 −$0.09 −$0.06 +33.3%
Sept 2025 −$0.11 −$0.14 −23.5%

Adjusted EPS as companies report it, against the average analyst estimate.

Analyst recommendations

5 analysts, Oct 2026
Buy5100%
Hold00%
Sell00%

Monthly trend

  1. Oct 2026145
  2. Sep 2026145
  3. Aug 2026145
  4. Jul 2026145

Counts of recommendations published by analysts covering Starling Oncology, Inc., by month. Source: Aggregated broker recommendations (third-party data). Aggregated counts only: we do not reproduce any firm's recommendation or price target, and these are not Fundamentalytics ratings.

Positioning

Short interest
7.3%
of tradable shares
Days to cover
4.75
at average volume
Short interest, 1 month
−7%
to October 15, 2026
Held by institutions
47%
of shares
Held by insiders
17.8%
of shares
Employees
641
full time

Consensus figures average analysts' published estimates (third-party data); guidance is the company's own. Neither is our forecast. Short interest is reported twice a month and lags. Market data may be delayed.

This section is general information, not investment advice or a personal recommendation, and it does not take account of your objectives or circumstances. Forecasts and guidance are estimates, not promises: companies miss their own guidance and analysts' figures are often revised. Prices can fall as well as rise, and you can lose money. See our disclaimer.

Share-price performance

Market data may be delayed

Recent prices are available. Older price history and the statistics that need it are being loaded in the background.

What moved the share price

Last 12 months +40.1%

$4.46 on October 31, 2025 to $6.25

ThenNowEffect
Revenue (last 12 months) $424m $587m +38.4%
P/S multiple 0.8x 1.1x +27.3%
Share count 80m 101m −20.4%

Biggest factor: revenue. Loss-making at one end, so the split uses price/sales.

Last 3 years +209.4%

$2.02 on November 3, 2023 to $6.25

ThenNowEffect
Revenue (last 12 months) $293m $587m +100.5%
P/S multiple 0.6x 1.1x +94.4%
Share count 80m 101m −20.6%

Biggest factor: revenue. Loss-making at one end, so the split uses price/sales.

The effects multiply back to the price change exactly. Results are the last 12 months as known on each date (filings assumed public 45 days after quarter end).

Return and risk by year

Calendar year 202120222023202420252026 to date
Return
STLN−10%−83%+24%−85%+1052%+76%
Industry peers (median)−1%−25%+6%−6%−9%+15%
S&P 500+29%−18%+26%+25%+18%+11%
Months that ended higher
STLN58%42%50%25%67%73%
S&P 50075%42%67%75%75%46%
Largest fall from a high during the year
STLN−46%−91%−79%−94%−39%−45%
S&P 500−5%−25%−10%−8%−19%−9%

Worst fall since June 4, 2020: 99% from February 19, 2021 to November 20, 2024. Getting back needed a 8453% gain, and the shares have not yet recovered.

Price behaviour

52-week range
$2.38 – $7.05
From 52-week high
−11.3%
vs 50-day average
−3.3%
vs 200-day average
+32.7%
Volatility (1 year)
80%
Beta vs S&P 500
1.61

Volatility is the annualised standard deviation of daily returns. Beta 1.5 means the shares typically moved 1.5% for each 1% move in the S&P 500 over the past year. Prices to November 2, 2026.

Share price after results

Next day
6 up, 6 down
typical move ±14.1%
After a week
5 up, 7 down
typical move ±18.2%
After a month
5 up, 7 down
typical move ±39.4%
Results releasedNext dayS&P 500 next day5 days21 days
August 6, 2026 +27.4% +0.5% +24.5% +17.9%
May 7, 2026 +5.3% +0.5% +6.3% +33.4%
March 12, 2026 +2.9% −2.1% +28.3% +19.6%
January 12, 2026 −15.6% 0.0% −17.7% −37.3%
November 13, 2025 +15.7% −1.7% −5.5% +9.9%
August 13, 2025 −10.7% +0.4% −9.0% −25.8%
May 14, 2025 +14.7% +0.6% +0.9% −6.8%
March 24, 2025 +26.5% +2.0% +14.5% +189.2%
November 13, 2024 −19.0% −0.6% −54.5% −23.1%
August 13, 2024 −7.2% +2.0% −17.5% −38.1%
May 14, 2024 −21.3% +1.7% −31.4% −46.6%
April 3, 2024 −2.6% −1.1% −8.4% −24.7%

From the close before the release date to the close 1, 5 and 21 trading days after it, so releases before the open and after the close are both captured. Past moves don't predict future ones.

Starling Oncology, Inc. in five measures

Fundamentals grade C
Growth Profitability Cash Balance sheet

Growth, profitability, cash generation and balance sheet are percentiles against the companies we cover in the same industry, from SEC filings (100 = best). Value compares the share price with our modelled value range (50 = at our base value; higher = cheaper). A description of reported data and our model — not a quality score or advice.

Fundamentals

Revenue (TTM) Starling Oncology, Inc.
$300M $400M $500M $600M FY23 Q3 FY24 Q2 FY25 Q1 FY26 Q2 Revenue (TTM), FY23 Q3: $309.9M Revenue (TTM), FY23 Q4: $324.2M Revenue (TTM), FY24 Q1: $342.7M Revenue (TTM), FY24 Q2: $361.1M Revenue (TTM), FY24 Q3: $378.9M Revenue (TTM), FY24 Q4: $393.4M Revenue (TTM), FY25 Q1: $403.2M Revenue (TTM), FY25 Q2: $424.4M Revenue (TTM), FY25 Q3: $461M Revenue (TTM), FY25 Q4: $502.7M Revenue (TTM), FY26 Q1: $545.8M Revenue (TTM), FY26 Q2: $587.2M $587.2M

Source: SEC EDGAR filings. Retrieved October 29, 2026.

View chart data
Period Revenue (TTM)
FY23 Q3 $309.9M
FY23 Q4 $324.2M
FY24 Q1 $342.7M
FY24 Q2 $361.1M
FY24 Q3 $378.9M
FY24 Q4 $393.4M
FY25 Q1 $403.2M
FY25 Q2 $424.4M
FY25 Q3 $461M
FY25 Q4 $502.7M
FY26 Q1 $545.8M
FY26 Q2 $587.2M
Revenue growth, TTM YoY Starling Oncology, Inc.
10% 20% 30% 40% FY23 Q3 FY24 Q2 FY25 Q1 FY26 Q2 Revenue growth, TTM YoY, FY23 Q3: 32.8% Revenue growth, TTM YoY, FY23 Q4: 28.4% Revenue growth, TTM YoY, FY24 Q1: 25.3% Revenue growth, TTM YoY, FY24 Q2: 23.3% Revenue growth, TTM YoY, FY24 Q3: 22.3% Revenue growth, TTM YoY, FY24 Q4: 21.3% Revenue growth, TTM YoY, FY25 Q1: 17.6% Revenue growth, TTM YoY, FY25 Q2: 17.5% Revenue growth, TTM YoY, FY25 Q3: 21.7% Revenue growth, TTM YoY, FY25 Q4: 27.8% Revenue growth, TTM YoY, FY26 Q1: 35.4% Revenue growth, TTM YoY, FY26 Q2: 38.4% 38.4%

Source: SEC EDGAR filings. Retrieved October 29, 2026.

View chart data
Period Revenue growth, TTM YoY
FY23 Q3 32.8%
FY23 Q4 28.4%
FY24 Q1 25.3%
FY24 Q2 23.3%
FY24 Q3 22.3%
FY24 Q4 21.3%
FY25 Q1 17.6%
FY25 Q2 17.5%
FY25 Q3 21.7%
FY25 Q4 27.8%
FY26 Q1 35.4%
FY26 Q2 38.4%
Operating margin (TTM) Starling Oncology, Inc.
-30% -20% -10% 0% FY23 Q3 FY24 Q2 FY25 Q1 FY26 Q2 Operating margin (TTM), FY23 Q3: -28.0% Operating margin (TTM), FY23 Q4: -23.8% Operating margin (TTM), FY24 Q1: -18.1% Operating margin (TTM), FY24 Q2: -17.6% Operating margin (TTM), FY24 Q3: -16.8% Operating margin (TTM), FY24 Q4: -15.3% Operating margin (TTM), FY25 Q1: -12.9% Operating margin (TTM), FY25 Q2: -11.1% Operating margin (TTM), FY25 Q3: -8.9% Operating margin (TTM), FY25 Q4: -7.2% Operating margin (TTM), FY26 Q1: -6.0% Operating margin (TTM), FY26 Q2: -4.4% -4.4%

Source: SEC EDGAR filings. Retrieved October 29, 2026.

View chart data
Period Operating margin (TTM)
FY23 Q3 -28.0%
FY23 Q4 -23.8%
FY24 Q1 -18.1%
FY24 Q2 -17.6%
FY24 Q3 -16.8%
FY24 Q4 -15.3%
FY25 Q1 -12.9%
FY25 Q2 -11.1%
FY25 Q3 -8.9%
FY25 Q4 -7.2%
FY26 Q1 -6.0%
FY26 Q2 -4.4%
FCF margin (TTM) Starling Oncology, Inc.
-20% -15% -10% -5% 0% FY23 Q3 FY24 Q2 FY25 Q1 FY26 Q2 FCF margin (TTM), FY23 Q3: -16.8% FCF margin (TTM), FY23 Q4: -12.6% FCF margin (TTM), FY24 Q1: -11.7% FCF margin (TTM), FY24 Q2: -13.3% FCF margin (TTM), FY24 Q3: -9.9% FCF margin (TTM), FY24 Q4: -7.8% FCF margin (TTM), FY25 Q1: -4.8% FCF margin (TTM), FY25 Q2: -3.1% FCF margin (TTM), FY25 Q3: -6.0% FCF margin (TTM), FY25 Q4: -5.5% FCF margin (TTM), FY26 Q1: -4.7% FCF margin (TTM), FY26 Q2: -0.6% -0.6%

Source: SEC EDGAR filings. Retrieved October 29, 2026.

View chart data
Period FCF margin (TTM)
FY23 Q3 -16.8%
FY23 Q4 -12.6%
FY24 Q1 -11.7%
FY24 Q2 -13.3%
FY24 Q3 -9.9%
FY24 Q4 -7.8%
FY25 Q1 -4.8%
FY25 Q2 -3.1%
FY25 Q3 -6.0%
FY25 Q4 -5.5%
FY26 Q1 -4.7%
FY26 Q2 -0.6%

Data: SEC EDGAR XBRL company facts (as filed in 10-K/10-Q); forms 10-K, 10-K/A, 10-Q, 10-Q/A. Generated November 3, 2026. Definitions in our methodology.

Financial statements

US$ millions unless shown otherwise. Fiscal years, plus the last twelve months (LTM) when newer.

Fiscal year 2020 Dec 2020 2021 Dec 2021 2022 Dec 2022 2023 Dec 2023 2024 Dec 2024 2025 Dec 2025 LTM Jun 2026
Income
Revenue 188 203 252 324 393 503 587
EBITDA −5 −43 −78 −71 −54 −29 −19
Operating income −8 −46 −82 −77 −60 −36 −26
Net income −14 −11 0 −83 −65 −61 −36
Diluted EPS −$0.24 −$0.16 −$0.21 −$0.92 −$0.71 −$0.54 −$0.36
Growth (year on year)
Revenue — +8.3% +24.4% +28.4% +21.3% +27.8% +38.4%
Margins
EBITDA margin −2.7% −20.9% −30.7% −21.9% −13.7% −5.8% −3.3%
Operating margin −4.4% −22.6% −32.5% −23.8% −15.3% −7.2% −4.4%
Net margin −7.6% −5.4% 0.1% −25.6% −16.4% −12.1% −6.2%
Free-cash-flow margin −0.4% −17.5% −26.6% −12.6% −7.7% −5.5% −0.6%
Cash flow
Cash from operations 1 −33 −62 −36 −27 −25 0
Capital spending 1 3 6 5 4 3 4
Free cash flow −1 −36 −67 −41 −30 −28 −3
Stock-based pay 0 25 28 18 11 5 5
Free cash flow after stock pay −1 −60 −95 −59 −41 −32 −8
Balance sheet
Cash 1 115 14 33 50 34 41
Total debt 12 0 110 110 110 86 86
Net debt (negative = net cash) 11 −115 96 77 60 52 45
Diluted shares 59m 66m 81m 74m 75m 92m 101m
Returned to shareholders
Buybacks — 0 9 1 0 — —
Total returned — 0 9 1 0 — —

Source: SEC EDGAR XBRL company facts (US and foreign periodic filings); column headings link to the filing. EBITDA is operating income plus depreciation and amortisation. Free cash flow is cash from operations minus capital spending. Growth is left blank when last year's figure was a loss or under 2% of revenue. Share counts and EPS are restated for stock splits. A dash means the company didn't report the figure.

Financial health

2 of 5 checks passed · June 30, 2026
What it owns · $178m
Short-term assets $129mLonger-term assets $49m
What it owes, and who funded it · $203m
Short-term liabilities $95mLonger-term liabilities $108mShareholders' equity $-25m
  • Short-term assets cover short-term liabilities $129m of assets due within a year against $95m of liabilities due within a year.
  • Short-term assets cover long-term liabilities $129m short-term assets against $108m of longer-dated liabilities.
  • More cash than debt $41m of cash against $80m of debt.
  • Debt below 40% of shareholders' equity Equity or debt not reported. Not assessable.
  • Debt burden no higher than five years ago Five-year comparison not available. Not assessable.
  • A year's operating cash flow covers at least 20% of debt $328,000 of operating cash flow against $80m of debt.
  • Operating profit covers interest at least five times over Operating income of −$26m against $8m of interest.

From Starling Oncology, Inc.'s latest balance sheet as filed. Checks are fixed, documented rules (methodology), counted only where the company reports the figures — a dot means the filing doesn't break the item out. Descriptions of reported data, not advice.

Dividends, buybacks and capital spending

Diluted share count
+25.7%
year over year
Sales & admin spending
19.0%
of revenue
Days sales outstanding
41 days
receivables vs revenue

Competitors: side by side with peers

Closest by revenue in health care services
Last 12 months unless stated STLN CDNA USPH CRVL INNV PNTG Median
Revenue, last 12 months $587m $497m $812m $984m $990m $1.1bn $1.2bn
Revenue growth, last 12 months 38.4% 38.9% 11.3% 7.1% 15.9% 37.9% 7.3%
Revenue growth, 3-year average 26.1% 18.7% 11.8% 10.3% 12.9% 30.0% 11.3%
Revenue growth, latest quarter 34.6% 39.3% 8.5% 10.7% 18.3% 35.8% 8.5%
Gross margin — 65.5% 18.7% 24.8% 23.0% — 27.9%
Operating margin −4.4% 23.4% 9.4% — 0.3% 5.6% 2.3%
Operating margin, 3-year average −11.0% −4.4% 9.0% — −2.1% 5.5% 2.3%
Net margin −6.2% 25.9% 4.0% 11.7% −0.3% 2.9% 1.2%
Cash from operations / revenue 0.1% 13.9% 10.2% 15.3% 6.5% 4.8% 6.1%
Free-cash-flow margin −0.6% 10.3% 7.9% 11.6% 5.1% 3.1% 5.1%
Free-cash-flow margin, 3-year average −5.7% 5.3% 9.0% 10.3% 0.8% 3.5% 3.6%
Stock pay / revenue 0.9% 7.7% 1.1% 0.5% 0.7% 0.9% 1.1%
Change in share count 25.7% −9.3% 0.2% −1.2% 0.2% 3.6% 0.3%

Median of all 41 companies we cover in health care services. Shaded: best of the six on that line (lowest for stock pay and share-count growth). 3-year figures average the last three 12-month periods; 3-year growth is compound annual. Source: SEC filings.

Peer comparison

41 health care services companies
Measure Company Peer median Rank
Revenue growth Growth 38.4% 7.3% 5 of 41
Change in growth rate Growth +3.0pp +1.1pp 14 of 41
Operating margin Profitability -4.4% 2.6% 27 of 40
Net margin Profitability -6.2% 1.2% 29 of 41
Free-cash-flow margin Cash generation -0.6% 5.1% 29 of 40
Stock pay as % of revenue Cash generation 0.9% 0.9% 15 of 35
Long-term debt as % of assets Balance sheet 44.8% 27.7% 26 of 31
Change in share count Balance sheet 25.7% 0.4% 35 of 39
Days sales outstanding Balance sheet 41 days 39 days 18 of 31

Rank 1 = best in the group (for spending, debt and dilution, lower ranks first).

Where the revenue comes from

Fiscal year to December 31, 2025
Segments
Line of business Revenue Share YoY
Specialty Pharmacy $269M 53.5% ▲ 49.6%
Patient Services $229M 45.5% ▲ 11.8%
Clinical Trials and Other $4.6M 0.9% ▼ 47.0%
Products and services
Line of business Revenue Share YoY
Health Care Specialty Pharmacy $269M 53.5% ▲ 49.6%
Health Care Patient Service $229M 45.5% ▲ 11.8%
Fee For Service $149M 64.9% ▲ 9.0%
Capitated Revenue $80.5M 35.1% ▲ 17.2%
Clinical Research Trials and Other Revenue $4.6M 0.9% ▼ 47.0%

From Starling Oncology, Inc.'s 10-K filed March 12, 2026, as tagged in the filing. View filing. Indented rows are part of the line above; their share is of that line. In the bars, the faint bar behind is the year before.

Who owns it

Funds buying and selling
Reported value
$218M
Institutions reporting
120
Shares held vs prior quarter
▲ 3.4%
Positions opened / closed
27 / 21

Top buyers and sellers, Q2 2026: 78 institutions bought and 46 sold ; the biggest buyer was Nuveen, LLC (+1.3M shares) and the biggest seller Kanen Wealth Management LLC (−2.8M). See which funds bought and sold →

Largest reported holders, June 30, 2026
Manager Value Shares Share of 13F value Shares QoQ
Blackrock, Inc. $25.8M 4.7M 11.9% ▲ 7.5%
Deerfield Management Company, L.P. $18.2M 3.4M 8.4% 0.0%
Vanguard Capital Management LLC $17.7M 3.3M 8.1% ▼ 6.1%
Josh Arnold Investment Consultant, LLC $13.4M 2.5M 6.1% 0.0%
Geode Capital Management, LLC $10.3M 1.9M 4.7% ▲ 8.1%
Goldman Sachs Group Inc $9.4M 1.7M 4.3% ▲ 28.4%
Wexford Capital LP $9.3M 1.7M 4.3% 0.0%
State Street Corp $8.4M 1.6M 3.9% ▲ 6.3%
Nuveen, LLC $7.6M 1.4M 3.5% ▲ 1378.8%
Renaissance Technologies LLC $7.4M 1.4M 3.4% ▲ 51.3%
Centerbook Partners LP $6.7M 1.2M 3.1% ▼ 20.8%
Marshall Wace, LLP $6.6M 1.2M 3.1% ▲ 257.2%

From Form 13F filings with the SEC ( quarterly data sets), as reported by each manager for June 30, 2026 and filed up to 45 days later. 13F reports cover long US-listed positions of managers above $100M only, so this is not Starling Oncology, Inc.'s complete shareholder register. Values are as reported by the filers .

Insider trading activity

Full insider history and chart
Insider purchases History → $2.7M 16 trades by 1 insider, last 12 months Insider sales History → $2.8M 11 trades by 5 insiders · 91% under pre-set plans
Net ▼ $122,184 net selling
Insider Date Trade Shares Price Value
Hively Brad Director August 21, 2026 Sell pre-set plan 298,853 $6.51 $1.9M
Chernett Jorey 10% owner August 14, 2026 Buy 12,000 $6.54 $78,480
Chernett Jorey 10% owner July 21, 2026 Buy 18,000 $5.27 $94,860
Podnos Yale Chief Medical Officer July 14, 2026 Sell pre-set plan 17,974 $6.43 $115,573
Podnos Yale Chief Medical Officer July 14, 2026 Sell pre-set plan 5,478 $6.35 $34,785
Chernett Jorey 10% owner July 10, 2026 Buy 15,000 $5.85 $87,750
Chernett Jorey 10% owner June 23, 2026 Buy 18,000 $5.02 $90,360
Podnos Yale Chief Medical Officer June 8, 2026 Sell pre-set plan 23,451 $5.38 $126,166
Chernett Jorey 10% owner June 4, 2026 Buy 12,000 $4.75 $57,000
Chernett Jorey 10% owner May 20, 2026 Buy 33,500 $4.07 $136,345
Chernett Jorey 10% owner May 19, 2026 Buy 30,000 $4.09 $122,700
Chernett Jorey 10% owner May 19, 2026 Buy 5,000 $4.05 $20,250

From insiders' Form 4 filings with the SEC. Excludes awards, option exercises and shares withheld for tax. "Pre-set plan" means the filing marks the trade as made under a Rule 10b5-1 plan. See every insider trade since five years ago, on a price chart.

Earnings dates and SEC filings

Results announcements

Next expected around October 21, 2026 estimated from the company's past filing pattern, not announced

  • August 6, 2026
  • May 7, 2026
  • March 12, 2026
  • January 12, 2026
  • November 13, 2025
  • August 13, 2025

Recent SEC filings

Data status

When each part of this page on Starling Oncology, Inc. was last updated.

DataLast updatedSource
Share priceExchange closing prices
Financial statementsSEC 10-K and 10-Q filings
News and updatesCompany releases and SEC 8-K filings
Analyst estimatesAggregated analyst estimates
Valuation and scoresOur models, from the filed figures

How we build and check these figures: methodology and data sources.

Starling Oncology, Inc. in brief

What does Starling Oncology, Inc. do?
Starling Oncology, Inc. is a US-listed company in the health care services industry. Its financial year ends in December.
What is Starling Oncology, Inc.'s stock ticker?
Starling Oncology, Inc. trades under the ticker STLN on Nasdaq. This page brings together its financial statements, valuation models, ownership and recent company updates.
What is Starling Oncology, Inc.'s revenue, and how fast is it growing?
Over its most recent trailing twelve months, Starling Oncology, Inc. reported revenue of $587M, 38.4% higher than a year earlier, according to its SEC filings.
What is Starling Oncology, Inc.'s free cash flow?
Starling Oncology, Inc.'s free-cash-flow margin is -0.6% of revenue over the trailing twelve months, ranking 29 of the 40 health care services companies we cover.
Who are Starling Oncology, Inc.'s largest institutional shareholders?
By value reported in 13F filings for June 30, 2026, the largest reported holders are Blackrock, Inc., Deerfield Management Company, L.P. and Vanguard Capital Management LLC. 13F reports cover long US-listed positions of managers above $100M, filed up to 45 days after quarter end.
What is Starling Oncology, Inc.'s market cap?
On November 2, 2026, Starling Oncology, Inc.'s market capitalisation was about $631M and net debt of $44.8M. Market figures come from third-party market data and may be delayed.
Who are Starling Oncology, Inc.'s competitors?
In our Health Care Services peer group, the companies closest to Starling Oncology, Inc. are Caredx, Inc., U S Physical Therapy Inc, Corvel Corp, Innovage Holding Corp. and Pennant Group, Inc. The side-by-side comparison below sets their revenue, margins and growth against Starling Oncology, Inc.'s.
Are insiders buying or selling Starling Oncology, Inc. stock?
Over the last 12 months, Starling Oncology, Inc.'s directors and officers reported 16 open-market purchases and 11 sales on Form 4. The insider trading page charts every trade.
When is Starling Oncology, Inc.'s next earnings date?
Around November 5, 2026, estimated from the spacing of its past results announcements (8-K filings). That is an estimate, not a confirmed date — Starling Oncology, Inc. announces its own schedule.